News | May 21, 2026
IOLCP revenue rises 11.5% YoY to Rs. 2,319.1 crore in FY26
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Patalganga plant received zero observation from USFDA earlier
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
The first of four planned modules at the new plant is expected to come online by summer 2026
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Subscribe To Our Newsletter & Stay Updated
